Effects of azithromycin on bronchial remodeling in the natural model of severe neutrophilic asthma in horses

• Published in: Scientific reports 2022-01, Vol.12 (1), p.446-446, Article 446
• Main Authors: Mainguy-Seers, Sophie, Boivin, Roxane, Pourali Dogaheh, Sheila, Beaudry, Francis, Hélie, Pierre, Bonilla, Alvaro G., Martin, James G., Lavoie, Jean-Pierre
• Format: Article
• Language: English
• Subjects: 631/250/2504/223/1699; 631/250/98; 631/443/1784; 692/420/256/2515; 692/699/1785/31; 692/700/565/1436/1437; 692/700/565/1436/2774; Administration, Inhalation; Airway Remodeling - drug effects; Animals; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antibiotics; Asthma; Asthma - drug therapy; Asthma - immunology; Asthma - veterinary; Azithromycin; Azithromycin - pharmacology; Azithromycin - therapeutic use; Bronchodilator Agents - administration & dosage; Corticoids; Corticosteroids; Drug Therapy, Combination; Female; Fluticasone; Fluticasone - administration & dosage; Histomorphometry; Horse Diseases - drug therapy; Horse Diseases - immunology; Horses; Humanities and Social Sciences; Inflammation; Leukocytes (neutrophilic); Male; multidisciplinary; Neutrophilia; Neutrophils; Phenotypes; Quality of life; Respiratory function; Respiratory tract; Respiratory tract diseases; Science; Science (multidisciplinary); Smooth muscle
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-021-03955-9

Steroid resistance in asthma has been associated with neutrophilic inflammation and severe manifestations of the disease. Macrolide add-on therapy can improve the quality of life and the exacerbation rate in refractory cases, possibly with greater effectiveness in neutrophilic phenotypes. The mechanisms leading to these beneficial effects are incompletely understood and whether macrolides potentiate the modulation of bronchial remodeling induced by inhaled corticosteroids (ICS) is unknown. The objective of this study was to determine if adding azithromycin to ICS leads to further improvement of lung function, airway inflammation and bronchial remodeling in severe asthma. The combination of azithromycin (10 mg/kg q48h PO) and inhaled fluticasone (2500 µg q12h) was compared to the sole administration of fluticasone for five months in a randomized blind trial where the lung function, airway inflammation and bronchial remodeling (histomorphometry of central and peripheral airways and endobronchial ultrasound) of horses with severe neutrophilic asthma were assessed. Although the proportional reduction of airway neutrophilia was significantly larger in the group receiving azithromycin, the lung function and the peripheral and central airway smooth muscle mass decreased similarly in both groups. Despite a better control of airway neutrophilia, azithromycin did not potentiate the other clinical effects of fluticasone.